Curis Inc - Company Profile
Powered by 
All the sales intelligence you need on Curis Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Curis Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Curis Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Curis Inc (Curis) is a biotechnology company that focuses on developing therapeutics for cancer treatment. The company's main activities include research and development of small molecule inhibitors targeting cancer-related pathways. The company's flagship product, emavusertib (CA-4948), is an orally available inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). Emavusertib has received Orphan Drug Designation for treating primary central nervous system lymphoma (PCNSL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). The company collaborates with partners such as Aurigene and the National Cancer Institute to advance its drug development programs. Curis is headquartered in Lexington, Massachusetts, the US.
Headquarters
United States of America
Address
128 Spring Street, Building C, Suite 500, Lexington, Massachusetts, 02421
Website
www.curis.com
Telephone
1 617 5036500
No of Employees
24
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CRIS (NASD)
Revenue (2024)
$9.4M
-13.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
82.5%
(2024 vs 2023)
Market Cap*
$1.6M
Net Profit Margin (2024)
XYZ
79.8%
(2024 vs 2023)
* As of and is in US$
Curis Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | Curis |
| Emavusertib | |
| Fimepinostat | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In November, the company sold its Erivedge Business. |
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with the University of Florida to investigate a drug known as emavusertib for people with advanced melanoma. |
| 2021 | Others | In December, the company was selected for addition to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF. |
Competitor Comparison
| Key Parameters | Curis Inc | AbbVie Inc | AstraZeneca Plc | Novartis AG | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Switzerland | Germany |
| City | Lexington | North Chicago | Cambridge | Basel | Leverkusen |
| State/Province | Massachusetts | Illinois | Cambridgeshire | Basel-Stadt | Nordrhein-Westfalen |
| No. of Employees | 24 | 57,000 | 96,100 | 75,267 | 87,830 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Martyn D. Greenacre | Chairman | Executive Board | 2017 | 84 |
| James E. Dentzer | President; Director; Chief Executive Officer | Executive Board | 2018 | 59 |
| Diantha Duvall | Chief Financial Officer | Senior Management | 2022 | 53 |
| Robert Martell, M.D., Ph.D. | Chief Scientific Officer | Senior Management | 2023 | - |
| Jonathan Zung, Ph.D. | Chief Development Officer | Senior Management | 2023 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer